Glucose promotes bacterial growth. Sodium-glucose transporter 2 inhibition (SGLT2i), which prevents glucose recovery from the urine, is standard therapy in chronic kidney diseases.
However, kidney bacterial infection rates did not increase. Here, we investigated possible underlying mechanisms contributing to this effect.
Kidney International published a clinical update in Research Highlights on 19 Jan 2026.
The item focuses on Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q.
Review the original article for the full source wording and details.